Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Accumulated Expenses (2020 - 2025)

Bioventus (BVS) has disclosed Accumulated Expenses for 4 consecutive years, with $119.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses changed N/A year-over-year to $119.4 million, compared with a TTM value of $119.4 million through Sep 2025, changed N/A, and an annual FY2024 reading of $135.9 million, changed N/A over the prior year.
  • Accumulated Expenses was $119.4 million for Q3 2025 at Bioventus, down from $135.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $135.9 million in Q4 2024 and bottomed at $111.6 million in Q4 2022.
  • Average Accumulated Expenses over 4 years is $124.6 million, with a median of $124.8 million recorded in 2022.
  • Peak annual rise in Accumulated Expenses hit 15.14% in 2022, while the deepest fall reached 15.14% in 2022.
  • Year by year, Accumulated Expenses stood at $131.5 million in 2021, then decreased by 15.14% to $111.6 million in 2022, then grew by 21.79% to $135.9 million in 2024, then decreased by 12.09% to $119.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for BVS at $119.4 million in Q3 2025, $135.9 million in Q4 2024, and $111.6 million in Q4 2022.